Position in LLY
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$430,595
+$94,879 QoQ
Shares Held
359
-1.6% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#3,873
of 4,605 holders
Holding Since
Mar 2024
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LLY Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026TRILLIUM ASSET MANAGEMENT, LLC holds $65,640,925 across 8 Drug Manufacturers - General names. LLY ranks #7 (0.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AZN |
Astrazeneca PLC
|
208,971 | $39,625,081 | |
| 2 | MRK |
Merck & Co., Inc.
|
87,017 | $11,181,684 | |
| 3 | GILD |
Gilead Sciences, Inc.
|
75,118 | $9,490,408 | |
| 4 | JNJ |
Johnson & Johnson
|
11,314 | $2,873,416 | |
| 5 | NVO |
Novo Nordisk A S
|
19,689 | $943,890 | |
| 6 | ABBV |
AbbVie Inc.
|
2,843 | $715,412 | |
| 7 | LLY |
ELI LILLY & Co
This page
|
359 | $430,595 | |
| 8 | PFE |
Pfizer Inc
|
15,799 | $380,439 |
All Filings in LLY
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $430,595 | 359 | Shares | Defined | 2026-08-11 | |
| 2026-03-31 | $335,716 | 365 | Shares | Defined | 2026-05-11 | |
| 2025-12-31 | $385,810 | 359 | Shares | Defined | 2026-02-13 | |
| 2025-09-30 | $338,772 | 444 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $348,449 | 447 | Shares | Defined | 2025-08-06 | |
| 2025-03-31 | $259,335 | 314 | Shares | Defined | 2025-05-13 | |
| 2024-12-31 | $242,408 | 314 | Shares | Defined | 2025-02-11 | |
| 2024-09-30 | $278,185 | 314 | Shares | Defined | 2024-11-07 | |
| 2024-06-30 | $303,302 | 335 | Shares | Defined | 2024-08-08 | |
| 2024-03-31 | $260,616 | 335 | Shares | Defined | 2024-05-09 | |
| No filing history on record for this holder in this stock. | ||||||